Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association.
about
Common standards of basal insulin titration in type 2 diabetesInsulin use early in the course of type 2 diabetes mellitus: the ORIGIN trialSelf-directed learning can outperform direct instruction in the course of a modern German medical curriculum - results of a mixed methods trial.Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.Self-monitoring of blood glucose in diabetes: from evidence to clinical reality in Central and Eastern Europe--recommendations from the international Central-Eastern European expert group.The evolving place of incretin-based therapies in type 2 diabetesIs the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis[Improvements in type 2 diabetes care? Pooled analysis of survey data in southern Germany (KORA) from 1999-2008].Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baselineBarriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study.Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis.A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registryEffect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study.Substantial increase in incidence of severe hypoglycemia between 1997-2000 and 2007-2010: a German longitudinal population-based studyDo We Need Updated Guidelines on the Use of Insulin Pump Therapy in Type 2 Diabetes? A Review of National and International Practice Guidelines.Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registryEffectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PClinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE.Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemiaEmerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesSafety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.DiaSurg 2 trial--surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial--DRKS00004550.The treatment of type 2 diabetes.Impact of Disease Management Programs on HbA1c Values in Type 2 Diabetes Patients in GermanySmall molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.The Karlsburg Diabetes Management System: translation from research to eHealth application.Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.Immortal time bias and survival in patients who self-monitor blood glucose in the Retrolective Study: self-monitoring of Blood Glucose and Outcome in Patients with Type 2 Diabetes (ROSSO).Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.
P2860
Q27009355-26528DB1-DC45-49D3-B854-1E02745C7BB1Q27024597-0C3D2408-E226-4E30-AB59-0B18A13E90ACQ27308676-A5BB239D-ECF4-43B7-9AF9-91B1C483BAE2Q33785162-7B83221A-9251-44B2-B8F2-314D4C47C69BQ33820072-1079905B-4E2A-4F43-BB28-A1A751A61E24Q33866808-8AA1ABB1-B2CA-4B9E-A472-9818B1ACF039Q33880174-F3907F3D-EF48-48D8-BE36-2D346C4E22B3Q34052978-356EB57A-6F23-479A-8788-1A0BDDE563DFQ34173849-D74A407D-BF5F-4099-A4AF-A22866132021Q34222009-F1B4CF60-A6D1-4A78-9588-7C4FC96D8925Q34586376-DC3C662A-CEEE-4074-8733-0EC417CB7226Q34982256-BA292FF9-B1DE-4799-B68B-E0FE0CC19F7BQ35073584-4B987F2A-379C-481F-9DBE-71DBD37473FCQ35183113-14799A1E-D777-4D4E-BE2C-CAD4CBCE05E8Q35337177-079796B3-E1EF-4F9F-87AA-BFE3A24007B9Q35663730-933B0271-B7B5-4A6A-93E0-5FF8A78B7C34Q35898288-342A0A9F-74C2-42F8-B4D4-64BD6D3D90B2Q36130870-72798722-46B6-4D18-918D-35B9C3DCEE31Q36134920-05D17DE7-898B-4CE0-8C3C-0FB55790926BQ36274368-0C312946-93CF-4BE4-8150-2DCA75419886Q36428057-F5DC48C3-A3FE-4511-8859-7DE0CBFEAFCDQ36430326-AC7BF3D4-592D-462B-A62F-98A9FA0AD265Q36520758-B5AB3160-2E2D-4B95-90DE-9C469F4816D6Q36941721-6763BF17-3BF7-4CF3-B022-20A5EA21CB09Q36959940-4AC351A9-C704-4358-8D39-5290A8DE9549Q37634244-50E4E9D3-E637-4686-A469-EE20EFE43E2DQ37732198-BF88484E-296A-4F7A-9129-F7D253B4F888Q37866299-972F97C6-5DA0-4D68-9E64-FA4C204DFED2Q37929159-FEF7DA3A-5874-4838-88E2-FB7A136E939FQ41961855-870AC930-9020-4C53-8B99-B87923F53E80Q42011083-62643312-72AB-4772-AC2F-6D58B2293AF5Q42613301-5D4C1D0F-691B-4044-88CF-06A4D6997200Q44521789-91AFE030-B9DD-4249-8659-8FAC6D760719Q45402744-7A34CBAA-2CF7-4A12-AF87-0DFC644845F5Q47690129-6A4D6BB4-DAEF-4639-80A1-44278F3C0772Q47766606-E16C56D5-96CB-4FFA-A193-7EBA9EAC683AQ47770450-C9263CD8-2C0A-4845-A233-B5EF704E7580
P2860
Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Medical antihyperglycaemic tre ...... e German Diabetes Association.
@en
Medical antihyperglycaemic tre ...... e German Diabetes Association.
@nl
type
label
Medical antihyperglycaemic tre ...... e German Diabetes Association.
@en
Medical antihyperglycaemic tre ...... e German Diabetes Association.
@nl
prefLabel
Medical antihyperglycaemic tre ...... e German Diabetes Association.
@en
Medical antihyperglycaemic tre ...... e German Diabetes Association.
@nl
P2093
P356
P1476
Medical antihyperglycaemic tre ...... e German Diabetes Association.
@en
P2093
A Fritsche
B Gallwitz
G Schernthaner
German Diabetes Association
H-U Häring
M Kellerer
P304
P356
10.1055/S-0029-1239559
P577
2009-10-29T00:00:00Z